Alpha Teknova Earnings Call Charts Cautious Recovery

Alpha Teknova, Inc. ((TKNO)) has held its Q4 earnings call. Read on for the main highlights of the call.

Alpha Teknova’s latest earnings call struck a cautiously optimistic tone, as management highlighted a sixth straight quarter of revenue growth, sharply better gross margins, and narrowing losses while acknowledging persistent cash burn and market uncertainty. Executives framed the business as on a credible path toward profitability by 2027, but stressed that execution and a healthier biotech funding backdrop remain critical.

Revenue Growth and Momentum

Teknova reported full‑year 2025 revenue of $40.5 million, up 7% from $37.7 million in 2024, underscoring steady top‑line momentum despite a choppy biopharma environment. Fourth‑quarter revenue rose 8% year over year to $10.0 million, marking the sixth consecutive quarter of growth and signaling that the company’s recovery is gaining durability.

Catalog and Lab Essentials Performance

Catalog products were the primary growth engine, delivering low double‑digit gains versus 2024 as customers leaned on ready‑to‑use reagents and media. Lab Essentials revenue reached $31.0 million in 2025, up 7% year over year, with roughly three‑quarters of that segment’s sales coming from the higher‑margin, scalable catalog portfolio.

Clinical Solutions Acceleration

The Clinical Solutions segment showed faster growth but from a smaller base, with fourth‑quarter revenue climbing 47% year over year to $2.7 million and full‑year sales up 8% to $7.7 million. The customer base expanded meaningfully as clinical customers rose from 48 in 2024 to 60 in 2025, a 25% increase that broadens Teknova’s future opportunity set.

Clinical Pipeline Traction

Management emphasized increasing embeddedness in customers’ development programs, noting Teknova now supports at least 70 therapies, up from the prior year. That includes five programs in Phase II or later and 12 in Phase I, and the company reiterated expectations of supporting at least one commercial therapy by the end of 2027, which could provide a higher‑quality revenue stream.

Gross Margin and Profitability Improvement

Profitability metrics showed significant progress as gross profit nearly doubled to $13.4 million in 2025 from $7.2 million in 2024, helped by higher volumes and manufacturing efficiencies. Gross margin improved to 33.2% for the year and 32.5% in Q4, versus 19.2% and 23.0% respectively a year earlier, though comparisons are flattered by a one‑time $2.8 million inventory charge in 2024.

Adjusted EBITDA and Net Loss Improvements

Loss metrics moved in the right direction, with adjusted EBITDA improving to negative $6.7 million for 2025 from negative $14.5 million a year earlier and Q4 adjusted EBITDA narrowing to negative $1.8 million. Net loss shrank to $17.3 million, or $0.32 per share, from $26.7 million, or $0.57 per share, reflecting both cost discipline and expanding gross profit.

Cash Flow and Balance Sheet Progress

Cash usage eased as free cash outflow improved to negative $9.8 million in 2025 from negative $13.5 million in 2024, beating prior guidance for less than $12 million of burn. The company ended the year with $21.3 million in cash, cash equivalents and short‑term investments against $13.2 million of gross debt, giving Teknova some runway to fund its growth plan.

Operational Metrics and Cost Discipline

Operational performance remained strong, with the company delivering around 95% of products on time and maintaining approximately 95% annual customer retention across a base of more than 3,000 customers. Revenue concentration appears limited as the top 10 Lab Essentials customers accounted for only 18% of sales, while headcount fell to 158 from 173 and operating expenses excluding nonrecurring items stayed below $8 million for seven straight quarters.

Forward‑Looking Targets and Investment Plan

Teknova laid out a measured growth agenda, guiding 2026 revenue to $42 million to $44 million, implying mid‑single‑digit growth and planning roughly $2 million in incremental commercial investment to accelerate demand. Management reiterated its goal of reaching adjusted EBITDA breakeven by the end of 2027 once annualized revenue hits roughly $52 million to $57 million, with each additional dollar of revenue expected to contribute about 70% to marginal cash flow.

Continued Negative Adjusted EBITDA and Cash Burn

Despite progress, Teknova remains in investment mode, with adjusted EBITDA still negative $6.7 million in 2025 and free cash flow outflow at $9.8 million. The company expects free cash outflow to remain below but near $10 million in 2026 as it steps up sales and marketing, leaving investors watching how quickly new spending converts into sustained revenue.

Net Losses Persist

The narrowed net loss of $17.3 million underscores momentum but also highlights that Teknova is still multiple years away from consistent profitability on a GAAP basis. Management presented a path to improved earnings by leveraging fixed costs and margin expansion, but execution risk remains as the company works to close the gap to break‑even.

Decline in Average Revenue per Customer

One pressure point was declining average revenue per customer, as Lab Essentials revenue per account fell about 3% for the year and Clinical Solutions dropped 14% to roughly $128,000. Management linked the declines to the onboarding of newer, earlier‑stage customers that currently spend less, which could prove positive over time if these accounts scale but weighs on near‑term metrics.

Dependence on Biotech Funding Recovery

Teknova’s outlook is tightly tied to broader biotech funding trends, with management estimating roughly a four‑quarter lag between funding inflows and its own revenue. The company did not assume a major funding rebound in its 2026 guidance and indicated that a sustained upturn could start boosting biopharma revenue from late 2026, creating potential upside but also timing uncertainty.

Lumpiness and Order Concentration Risk in Clinical Solutions

Clinical Solutions remains susceptible to volatility because larger average order sizes and project timing can drive quarter‑to‑quarter swings in revenue. Executives noted they have yet to see a material increase in larger Clinical Solutions orders for 2026, reinforcing the segment’s lumpiness and the importance of growing the overall pipeline of programs.

Modest Near‑Term Guidance and Distorted Comparables

The 2026 revenue guidance midpoint of roughly 6% growth sits well below Teknova’s long‑term target of 20% to 25% annual growth, leaving a gap that must be bridged by stronger markets, internal investments, or potential deals. Year‑over‑year margin comparisons also remain somewhat distorted by the nonrecurring 2024 inventory charge, which makes underlying improvement appear more dramatic than the clean run‑rate trend.

Forward‑Looking Guidance and Long‑Term Ambitions

Looking ahead, Teknova expects 2026 gross margins in the mid‑30% range and aims to keep free cash outflow under $10 million while absorbing higher go‑to‑market spending. Management reiterated long‑term aspirations for 60% to 65% gross margins and 25% to 30% adjusted EBITDA margins, arguing that operating leverage, a richer mix of catalog and clinical revenue, and a healthier biotech cycle could push the company into sustainable profitability after 2027.

Teknova’s earnings call painted a picture of a company steadily strengthening its financial footing while still operating below the profitability line. With improving margins, tighter cost controls, and expanding clinical engagement, the story is turning more constructive, but investors will need to monitor cash burn, biotech funding trends, and the pace at which new commercial investments translate into faster growth.